New Drug to Treat HIV InfectionAschenbrenner, Diane S. MS, RNAJN The American Journal of Nursing: September 2011 - Volume 111 - Issue 9 - p 23 doi: 10.1097/01.NAJ.0000405055.38571.06 Drug Watch Abstract Author Information A new nonnucleoside reverse-transcriptase inhibitor (NNRTI), rilpivirine (Edurant), has been approved for the treatment of HIV and AIDS. Patients with an excessively high viral load shouldn't start taking rilpivirine because it will increase their risk of treatment failure; also, patients who've experienced treatment failure are more likely to develop resistance to other NNRTIs. Rilpivirine should be taken with a meal for maximum absorption. Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org. © 2011 Lippincott Williams & Wilkins, Inc.